GlassScriptPhysician profile
Syed Naseeruddin
NPI 1235187527
$5,412.38
in general payments reported to CMS, 2019-2025
28 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $430 · 2021: $896 · 2022: $652 · 2023: $1,470 · 2024: $377 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,570.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $504.97 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $466.97 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.82 | 2020-2025 | Jardiance |
| Pfizer INC. | $326.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $325.89 | 2019-2023 | |
| Lilly USA, LLC | $303.22 | 2019-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $257.96 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.12 | 2022-2025 | |
| Exact Sciences Corporation | $227.57 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $107.23 | 2019-2021 | |
| Amgen INC. | $96.57 | 2019-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $92.31 | 2019-2021 | |
| Abbvie INC. | $81.33 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $77.92 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $65.06 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $49.05 | 2020-2021 | |
| Ethicon US, LLC | $45.16 | 2019 | |
| Mylan Specialty L.P. | $29.57 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.34 | 2019-2024 | Eliquis |
| Sumitomo Pharma America, INC. | $28.41 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.81 | 2019-2023 | Trulance, Xifaxan |
| Lundbeck LLC | $24.38 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $19.38 | 2022 | |
| Antares Pharma, INC. | $18.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.78 | 2022 | |
| Shield Therapeutics INC | $12.60 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Naseeruddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.